News headlines about NanoString Technologies (NASDAQ:NSTG) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NanoString Technologies earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 47.7563809679067 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
NSTG has been the subject of several recent research reports. Zacks Investment Research cut shares of NanoString Technologies from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down previously from $13.00) on shares of NanoString Technologies in a report on Thursday, March 8th. Finally, ValuEngine cut shares of NanoString Technologies from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $13.06.
NSTG stock traded down $0.15 during midday trading on Wednesday, hitting $6.60. 109,865 shares of the stock were exchanged, compared to its average volume of 239,230. The company has a quick ratio of 2.84, a current ratio of 3.40 and a debt-to-equity ratio of 1.22. NanoString Technologies has a one year low of $5.87 and a one year high of $20.70.
In other NanoString Technologies news, Director William Young purchased 30,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were acquired at an average cost of $6.91 per share, with a total value of $207,300.00. Following the completion of the transaction, the director now owns 30,000 shares in the company, valued at $207,300. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 24.40% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This report was posted by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/21/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-nanostring-technologies-nstg-share-price/2029779.html.
About NanoString Technologies
NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.